Gyre Therapeutics (NASDAQ:GYRE – Get Free Report) announced its quarterly earnings results on Friday. Gyre Therapeutics had a negative net margin of 5.44% and a positive return on equity of 3.13%. Get Gyre Therapeutics alerts:Insider Buying and SellingIn other Gyre Therapeutics news, COO Weiguo Ye sold 12,820 shares of the stock in a transaction dated Thursday, May 21st. Zacks Research raised Gyre Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Monday, July 6th. See AlsoReceive News & Ratings for Gyre Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gyre Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.